Position:
Professor of Medicine
Division Head
Division:
AIDS
Group Website:
Address:
St. Paul’s Hospital Room 667
1081 Burrard Street
Vancouver, British Columbia V6Z 1Y6
Canada
Vision Statement:

Our work is aimed to use existing and novel evidence-based strategies to eliminate HIV related morbidity and mortality, as well as transmission.  We aim to achieve this locally, in BC, to develop the roadmap for HIV/AIDS elimination globally.  Critically, we feel that this goal cannot be achieved without addressing the unmet needs of the most affected populations (including MSM, people who use drugs, commercial sex workers, and First Nations), as well as the ongoing challenges posed by stigma, discrimination, criminalization, and political apathy.

Research Interests:

HIV/AIDS; antiretroviral therapy; Treatment as Prevention in HIV/AIDS; most-at-risk populations (MARPs)

Research Sumary:

Over the last three decades, our research has focused on the therapeutic control of HIV/AIDS.  Initially, we played a key role in establishing the efficacy of highly active antiretroviral therapy (HAART) that has now become the standard of care around the world.  Since then, we have optimized therapeutic strategies and, more recently, uncovered the secondary preventive potential of HAART and established the role of “Treatment as Prevention” to decrease morbidity, mortality, and HIV transmission.  This made-in-BC strategy, with the support of the provincial government, offers immediate treatment to all HIV-infected persons throughout BC. HIV has become a chronic and manageable disease and we continue to work with our global community to lead the way and make this the new global standard of care.

Education:
University of Buenos Aires, 1973, BA
University of Buenos Aires, 1979, MD
University of Buenos Aires, 1980, Internship
Hospital “Cosme Argerich”, University of Buenos Aires, 1981, Residency
Pulmonary Research Lab, St. Paul’s Hospital, 1983, Postdoctoral Fellow
UBC Department of Medicine, 1985, Residency
UBC Respiratory Division, 1986, Clinical Fellow
UBC-Department of Medicine, 1986, Chief Resident
UBC-Department of Medicine, 1987, Research Fellow
Affiliations
HIV/AIDS Program, St. Paul’s Hospital, Physician Program Director
UNAIDS, Special Advisor on HIV Treatment
Recent Publications:

(selected from over 600 peer-reviewed publications)

  • 1 Gelmon K, Fanning M, Falutz J, Montaner JSG, Tsoukas C, O’Shaughnessy M, Wainberg M, Ruedy J. Nature, time course and dose dependence of zidovudine related side effects. Results from the Multicentre Canadian Azidothymidine Trial. AIDS 1989;3(9) 555-561.
  • 2 Montaner JSG, Russell JR, Lawson LM, Ruedy J. Acute respiratory failure secondary to Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A potential role for systemic corticosteroids. Chest 1989;95(4):881-884.
  • 3 Masur H, Meier P, McCutchan JA, Feinberg J, Bozette SA, Clement M, Ellenberg SS, Feigal DW, Gagnon S, Mathers C.W, Mills J, Montaner JSG, Nielsen JO, Sattler FR, Spector S, Tilles JG. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. New Engl J Med 1990:1500-1504.
  • 4 Montaner JSG, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe AIDS-related Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113(1)15-20.
  • 5 Montaner JSG, Le T, Fanning M, Gelmon K, Tsoukas C, Falutz J, O’Shaughnessy M, Wainberg M, Ruedy J. The effect of zidovudine on platelet count in HIV infected individuals. JAIDS 1990;3(6):565-570.
  • 6 Wainberg MA, Tremblay M, Rooke R, Blain N, Soudeyns H, Parniak MA, Yao XJ, Li XG, Fanning M, Montaner JSG , O’Shaughnessy M, Tsoukas C, Falutz J, Dionne G, Belleau B, Ruedy J. Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1 – Results from the Canadian AZT Multicentre Study. Annals of New York Academy of Sciences 1990;616:346-355.
  • 7 Child S, Montaner JSG, Tsoukas C, Fanning M, Le T, Wall RA, Ruedy J. Canadian multicenter azidothymidine trial: AZT pharmacokinetics. JAIDS 1991;4(9):865-870.
  • 8 Montaner JSG, Lawson LM, Gervais A, Hyland R, Chan CK, Falutz J, Renzi PM, MacFadden D, Rachlis AR, Fong IW, Garber GE, Simor A, Gilmore N, Fanning M, Taylor GD, Martel AY, Schlech WF, Schechter MT. Aerosol Pentamidine for the secondary prophylaxis of AIDS-Related PCP. A randomized, placebo-controlled study. Ann Intern Med 1991;114(11):948-953.
  • 9 Montaner JSG, Le TN, Le N, Craib K, Schechter MT. Application of the World Health Organization System for HIV Infection in a Cohort of Homosexual Men in Developing a Prognostically Meaningful Staging System. AIDS 1992;6:719-724.
  • 10 Montaner JSG, Singer J, Schechter MT, Raboud JM, Tsoukas C, O’Shaughnessy M, Ruedy J, Nagai K, Salomon H, Spira B, Wainberg MA. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS 1993;7:189-196.
  • 11 Montaner JSG, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA, and the Canadian HIV Trials Network Protocol 002 Study Group. Didanosine compared with continued zidovudine therapy for HIV infected patients with 200 to 500 CD4 cells/mm3. A double blind, randomized, controlled trial. Ann Intern Med 1995; 123(8):561-71.
  • 12 Wainberg MA, Salomon H, Gu Z, Montaner JSG, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J, Nicholson W. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995;9(4):351-357.
  • 13 Montaner JSG, Hogg RS, Srour LF, Murphy C, Barber CG, Phillips P, O’Shaughnessy M, Schechter MT. Should we embrace new drugs with open arms? Experience from a community-based, open arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease. JAIDS 1996;13:422-426.
  • 14 Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Consensus Statement. Antiretroviral Therapy for HIV Infection in 1997. JAMA 1997;277(24):1962-1969.
  • 15 Hogg RS, Weber AE, Craib JKP, Anis AH, O’Shaughnesy MV, Schechter MT, Montaner JSG. One world, one hope: the cost of providing antiretroviral therapy to all nations. AIDS 1998; 12:2203-2209.
  • 16 Hogg, RS, Heath KV, Yip B, Craib KJP, O’Shaughnessy MV, Schechter MT, Montaner JSG. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279(6):450-454.
  • 17 Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Robinson P, Hall D, Myers M, Lange JMA. A randomized, double-blinded trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients. The INCAS Trial. JAMA 1998; 279(12):930-937.
  • 18 Hogg RS, Yip B, Kully C, Craib KJP, O’Shaughnessy MV, Schechter MT, Montaner JSG. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Can Med Assoc J 1999;160(5):659-665.
  • 19 Raboud JM, Rae S,Vella S, Harrigan PR, Bucciardini R, Fragola V, Ricciardulli D, Montaner JSG and the INCAS Study Team. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. JAIDS 1999;22:260-266.
  • 20 The AVANTI Steering Committee (Montaner JSG member). Analysis of HIV-1 clinical trials: statistical magic? Lancet 1999; 353(9169):2061-4.
  • 21 Montaner JSG, Harrigan R, Raboud J, Jahnke N, Castillo E, Hogg R, Yip B, O’Shaughnessy M. Multi-drug rescue therapy in three cohorts of HIV-positive individuals. Antiviral Therapy 2000;5(2):21-22.
  • 22 Wood E, Schechter MT, Tyndall MW, Montaner JSG, O’Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: two potential futures. AIDS 2000;14(9):1229-35.
  • 23 Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan RP, O’Shaughnessy MV, Montaner JSG. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 2000;14:1955-1960.
  • 24 Hogg RS, Yip B, Chan KJ, Wood E, Craib KJP, O’Shaughnessy MV, Montaner JSG. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286(20):2568-2577.
  • 25 Montaner JSG, Harrigan PR, Jahnke N, Raboud J, Castillo E, Hogg RS, Yip B, Harris M, Montessori V, O’Shaughnessy MV. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001;15:61-69.
  • 26 Montaner JSG, Hill A, Acosta E. Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet 2001; 357(9266):1438-40.
  • 27 Wood E, Tyndall MW, Spittal PM, Li K, Kerr T, Hogg RS,Montaner JSG, O’Shaughnessy MV, Schechter MT. Unsafe injection practices in a cohort of injection drug users in Vancouver: Could safer injecting rooms help? Can Med Assoc J 2001;165(4):405-10.
  • 28 Cote HCF, Brumme ZL, Craib KJP, Math M, Alexander CS, Wynhover B, Ting, L, Wong H, Harris M, Harrigan PR, O’Shaughnessy MV, Montaner JSG. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New Engl J Med 2002;346(11):811-820.
  • 29 Wood E, Hogg RS, Yip B, Tyndall MW, Sherlock CH, Harrigan RP, O’Shaughnessy MV, Montaner JSG. “Discordant” increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. JAIDS 2002;30(2):159-166.
  • 30 Cote H, Yip B, Asselin J, Chan J, Hogg R, Harrigan R, O’Shaughnessy MV, Montaner JSG. Mitochondrial: Nuclear DNA ratios in peripheral blood cells from Human Immunodeficiency Virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003;187:1972-6.
  • 31 Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JSG. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 109 cells/L. Ann Intern Med 2003;139(10):810-16.
  • 32 Wood E, Hogg RS, Yip B, Quercia R, Harrigan R, O’Shaughnessy MV, Montaner JSG. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis 2003; 188(10):1421-5.
  • 33 Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JS, Tyndall MW. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Can Med Assoc J 2004;171(7):731-4.
  • 34 Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, Guillemi S, Schechter MT, Montaner JSG. Staging for antiretroviral therapy among HIV-infected drug users. JAMA 2004;292(10):1175-1177.
  • 35 Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, Schechter MT, Tyndall MW. Rationale for evaluating North America’s first medically supervised safer-injecting facility. Lancet Infect Dis 2004;4(5):301-306.
  • 36 Wood E, Montaner JSG, Braitstein P, Schechter M, O’Shaughnessy MV, Hogg R. Elevated rates of antiretroviral therapy discontinuation among injection drug users: Implications for drug police and public health. Int J Drug Policy 2004;15:133-138.
  • 37 Wood E, Hogg RS, Harrigan PR, Montaner JSG. When to intiate antiretroviral therapy in HIV-1-infected adults: A review for clinicians and patients. Lancet Infect Dis 2005;5:407-14.
  • 38 Wood E, Tyndall MW, Stoltz JA, Small W, Zhang R, O’Connell J, Montaner JS, Kerr T. Safer injecting education for HIV prevention within a medically supervised safer injecting facility. Internat J Drug Policy 2005;16(4):281-4.
  • 39 Kerr T, Stoltz J, Tyndall M, Li K, Zhang R, Montaner J, Wood E. Impact of a medically supervised safer injection facility on community drug use patterns: A before and after study. British Medical Journal 2006; 332: 220-22.
  • 40 Levy AR, James D, Johnston K, Hogg RS, Harrigan PR, Harrigan BP, Sobolev B, Montaner JS. The direct costs of HIV/AIDS care: a review of the published studies. Lancet Infect Dis 2006;6:171-77.
  • 41 Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368(9534):531-536.
  • 42 Wood E, Tyndall MW, Lai C, Montaner JSG, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy 2006;1(1):13.
  • 43 Wood E, Tyndall MW, Qui Z, Zhang R, Montaner JS, Kerr T. Service uptake and characteristics of injection drug users utilizing North America’s first medically supervised safer injecting facility. Amer J Public Health 2006;96(5):770-73.
  • 44 Wood E, Tyndall MW, Zhang R, Stoltz JA, Lai C, Montaner JS, Kerr T. Attendance at supervised injecting facilities and use of detoxification services. New Engl J Med 2006;354(23):2512-14.
  • 45 Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ 2006;175(11):1399-1404.
  • 46 Wood E, Tyndall MW, Zhang R, Montaner JS, Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction 2007;102(6):916-9.
  • 47 Wood E, Kerr T, Tyndall MW, Zhang R, Hogg RS, Strathdee SA, Montaner JS. Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users. Addiction 2007;102(9):1503-5.
  • 48 Wood E, Kerr T, Montaner JS. HIV treatment, injection drug use, and illicit drug policies. Lancet 2007;370(9581):8-10.
  • 49 DeBeck K, Wood E, Zhang R, Tyndall M, Montaner JS, Kerr T. Police and public health partnerships: evidence from the evaluation of Vancouver’s supervised injection facility. Substance Abuse Treatment, Prevention and Policy. 2008 May 7;3:11.
  • 50 Kerr T, Montaner JS, Wood E. Misrepresentation of science undermines HIV prevention efforts. Canadian Medical Association Journal, 2008; 178(7): 964.
  • 51 Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, Montaner JSG. Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008;198(1 July):59-67.
  • 52 Marshall B, Livingstone C, Kerr T, Li K, Montaner JS, Wood E. High prevalence of HIV infection among homeless and street-involved Aboriginal youth in a Canadian setting. Harm Reduction Journal, 2008 Nov 19; 5:35.
  • 53 Wood E, Montaner JS, Li K, Zhang R, Barney L, Strathdee SA, Tyndall WA, Kerr T. Burden of HIV infection among aboriginal injection drug users in Canada. Am J Public Health 2008;98(3):515-519.
  • 54 Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, Montaner JSG. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008;300(5):550-54.
  • 55 Wood E, Montaner JS, Kerr T. Illicit drug addiction, infectious disease spread, and the need for an evidence-based response. Lancet 2008;8:142-43.
  • 56 Wood E, Kerr T, Tyndall M, Montaner JS. The Canadian government’s treatment of scientific process and evidence: inside the evaluation of North America’s first supervised injecting facility. International Journal of Drug Policy. 2008; 19(3): 220-225.
  • 57 Wood A, Wood E, Lai C, Tyndall M, Montaner JS, Kerr T. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver’s supervised injection facility. International Journal of Drug Policy. 2008 June;19(3): 183-188.
  • 58 Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS, Montaner JS, Harrigan PR. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2010 Jan 1; 50(1):98-105. PubMed PMID: 19951169
  • 59 Lima V, Fernandes Ki, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med. 2009 Mar; 68(6):1044-9. Epub 2009 PubMed PMID: 19157668
  • 60 Lima VD, Fink V, Yip B, Hogg RS, Harrigan PR, Montaner JS. Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals. Am J Public Health 2009;99(S1):S193-96.
  • 61 Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JS. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009;50(5):529-36.
  • 62 Wood E, Kerr T, Marshall DL, Li K, Zhang R, Hogg RS, Harrigan PR, Montaner JSG. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009;338;b1649.
  • 63 Wood E, Werb D, Marshall B, Montaner JS, Kerr T. The war on drugs: a devastating public policy disaster. Lancet. 2009; 373(9668): 989-990.
  • 64 Girard F, Ford N, Montaner J, Cahn P, Katabira E. HIV/AIDS. Universal access in the fight against HIV/AIDS. Science 2010;329(5988):147-9.
  • 65 Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Fustafson P, Briggs A, Montaner JS. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS 2010;24:1929-35.
  • 66 Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, Montaner JS. Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level. J Acquir Immune Defic Syndr. 2010 Sep 10. [Epub ahead of print] PubMed PMID: 20838225.
  • 67 Lima VD, Lepik KJ, Zhang W, Muldoon KA, Hogg RS, Montaner JSG. Regional and temporal changes in HIV-related mortality in British Columbia, 1987-2006. Can J Public Health 2010;101(5):514-19.
  • 68 Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010;376:532-39. (published online July 18. DOI:10.1016/S0140-6736(10)60936-1)
  • 69 Shoveller J, DeBeck K, Montaner J. Developing Canada’s research base for harm reduction and health equity approaches to HIV prevention and treatment. Can J Public Health 2010;101(6):442-44.
  • 70 Volkow ND, Montaner J. Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA 2010;303(14):1423-24.
  • 71 Antiretroviral Treatment of Adult HIV Infection-2008 Recommendations of the International AIDS Society-USA Panel. JAMA 1996;276(2):146-154; JAMA 1998; 280:78-86; JAMA 2000;283(3):381-391; JAMA 2002;288(2):222-235; JAMA 2004;292(2):251-65; JAMA 2006;296(7):827-43; JAMA 2008;300(5):555-70; JAMA 2010;304(3):321-33.
  • 72 Volkow ND, Montaner J. The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Affairs 2011;30(8):1411-19.
Awards & Recognition:
  • National Health Research Scholar, Health & Welfare Canada – Pathogenesis and Treatment of HIV and Related Diseases (1987-1997)
  • Martin Hoffman Award for Excellence in Research, Department of Medicine, UBC (1996)
  • AccolAIDS – Science, Research and Technology Award (2002)
  • Boehringer Ingelheim- Distinguished Researcher Award (2002)
  • AccolAIDS-Science/Research/Technology, Organization-BC Centre for Excellence in HIV/AIDS (2005)
  • Killam Prize for Senior Science Category, UBC (2007)
  • Distinguished Service Award, Department of Medicine, St. Paul’s Hospital, Providence Health Care, (2004)
  • Betty Fata Award for Conference Leadership, Tourism Vancouver (2004)
  • Sanofi Pasteur Award:  Conquering HIV/AIDS-Recognizing Canadians who Make a Difference (2006)
  • Distinguished Achievement Award for Overall Excellence, Faculty of Medicine, UBC (2007)
  • Research & Mission Award, Providence Health Care Research Institute (2007)
  • Science & Technology Champion of the Year Award, BC Innovation Council (2007)
  • Killam Prize, Senior Science Category, UBC (2007)
  • Placa al Mérito, Asociacion de Profesores Hispano-Canadienses, Consulate of the Republic of Argentina (2008)
  • Leadership Award, LifeSciences BC (2009)
  • CIHR Knowledge Translation Award (2009)
  • Aubrey J. Tingle Prize for Outstanding Leadership, Michael Smith Foundation for Health Research (2010)
  • Prix Galien Canada Research Award (2010)
  • Albert Einstein World Award of Science, World Cultural Council (2010)
  • BC Health Association Legacy Award, University of BC College of Health Disciplines (2011)
  • Jacob Biely Research Prize, UBC (2011)
  • Grand Decoration of Honour for Services to Austria, Government of Austria, (2012)
  • The Queen Elizabeth II Diamond Jubilee Medal (2012)
  • Hope is a Vaccine Award, Global Alliance to Immunize against AIDS (2012)
  • Canadian Medical Association Frederic Newton Gisborne Starr Award (2013)
  • HRF Medal of Honour, Rx&D Health Research Foundation (2013)
  • Distinguished Achievement Award, Faculty of Medicine, UBC (2013)

Distinctions:

  • President-Elect, International AIDS Society (2006-2008)
  • President-International AIDS Society (2008-2010)
  • Fellow, Category III-Division of Life Sciences, Royal Society of Canada (2009)
  • Past-President, International AIDS Society (2010-2012)
  • Fellow, American College of Physicians (2010)
  • Honorary Degree, Doctor of Science-honoris causa, Simon Fraser University, Burnaby, BC (2010)
  • Order of British Columbia (2010)
  • Honorary Degree, Doctor of Science-honoris causa, Cordoba University, Argentina (2012)
  • SENADOR DOMINGO FAUSTINO SARMIENTO, Argentina Senate of the Nation (2013)
  • Professor Honoris Causa, University of Buenos Aires (2013)
  • Quarter Century Club, University of British Columbia (2013)